IVIG Treatment for Refractory Immune-Related Adult Epilepsy

NCT01545518 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Futility criteria, unable for Phase 2 of study, \& phase 1 was terminated.

Conditions

Epilepsy, Cryptogenic
Epilepsy, Partial
Seizure Disorder
Autoimmune Diseases, Nervous System
Limbic Encephalitis

Interventions

DRUG: IVIG

Sponsor

Emory University

Collaborators

[object Object]